Yahoo
NYSE American - Delayed Quote USD

Regentis Biomaterials Ltd. (RGNT)

1.1900 +0.0200 (+1.71%)
At close: November 6 at 4:00:00 PM EST
1.1200 -0.0700 (-5.88%)
After hours: November 6 at 4:34:32 PM EST
Chart Range Bar
Loading chart for RGNT
  • Previous Close 1.1700
  • Open 1.1718
  • Bid 1.1000 x 50000
  • Ask 1.2000 x 30000
  • Day's Range 1.1649 - 1.2199
  • 52 Week Range 1.1600 - 15.5000
  • Volume 23,370
  • Avg. Volume 45,289
  • Market Cap (intraday) 8.358M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -2.4600
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 10.00
  • Moby Rating Neutral

Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.

www.regentis.co.il

--

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

RGNT
82.34%
S&P 500 (^GSPC)
7.76%

1-Year Return

RGNT
83.92%
S&P 500 (^GSPC)
9.77%

3-Year Return

RGNT
83.92%
S&P 500 (^GSPC)
68.96%

5-Year Return

RGNT
83.92%
S&P 500 (^GSPC)
57.04%

Analyst Insights

View More

Analyst Price Targets

10.00
10.00 Average
1.1900 Current
10.00 High

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -113.59%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -16.1M

  • Diluted EPS (ttm)

    -2.4600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.95M

  • Total Debt/Equity (mrq)

    0.38%

  • Levered Free Cash Flow (ttm)

    2.14M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: